Search

everythinglearnresearchcommunity

for

Search:↓

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Low-intensity ultrasound may help protect hair follicles from chemotherapy-induced hair loss.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Oral tofacitinib successfully treated total body hair loss in one patient.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

The new drug delivery system effectively targets lung cancer cells.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Tofacitinib may help treat severe hair loss, but more research is needed.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.